A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer

Summary

This is a Phase 1, open-label, dose escalation study to assess the safety, tolerability, and preliminary efficacy of SOT201 as monotherapy for participants aged 18 years or above with advanced unresectable or metastatic solid tumors During dose escalation, the recommended dose(s) of SOT201 given every 3 weeks (Q3W) will be determined

Timeline

Start

2024-05-01

Primary completion

2026-10

Completion

2026-10

Publications

• Matuskova H, Marasek P, Mazhara V, Simonova E, Kosinova L, Danek P, Danova K, Sajnerova K, Malatova I, Hrabankova K, Greco D, Martinec O, Fabisik M, Podzimkova N, Hladikova K, Behalova K, Antosova Z, Sirova M, Mikyskova R, Reinis M, Kovar M, Bechard D, Moebius U, Palova Jelinkova L, Spisek R, Steegmaier M, Adkins I. Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v. J Immunother Cancer. 2025 Apr 17;13(4):e010736. doi: 10.1136/jitc-2024-010736.

Drugs

Indications